Abstract: Bone scintigraphy is one of the first-line imaging modalities for the screening and follow up of bone metastasis in patients with prostate cancer. The amount (%) of bone metastasis can be calculated using a bone scan index thanks to recent advances in quantitative bone scintigraphy. Since an artificial neural network was applied for hot-spot characterization and quantitation, the bone scan index has become a simple, reproducible and practical means of quantifying bone metastasis. The bone scan index is presently considered as an imaging biomarker of bone metastasis. The present article summarizes the principles and application of bone scan index using dedicated software (EXINI bone in Europe and North America; BONENAVI in Japan), and the advantages and cautions of using the bone scan index. The bone scan index could serve as a practical marker with which to monitor disease progression and treatment effects in multicenter studies, and to manage prostate and other types of cancer in the clinical setting.
Introduction
Although recent advances in oncological treatment have helped to improve the survival of patients with prostate cancer, the appropriate management of bone metastasis has become increasingly important. The occurrence of bone metastasis worsens the QOL of cancer patients due to events associated with the skeleton, such as bone pain, pathological fractures, hypercalcemia and overall survival. Early diagnosis of bone metastasis and appropriate surrogate markers linked to relevant outcomes have therefore been investigated. 1 The BSI was developed as a marker of the total amount of bone metastasis using whole-body scintigraphy with 99m Tc-MDP. 2, 3 The BSI is now considered as an index, or imaging biomarker, of the extent of whole-body bone metastasis. The present article reviews the purpose of the BSI, how it is calculated, how it can be interpreted compared with conventional criteria, and the key benefit of using it for prognostic applications and to monitor treatment.
Need for quantitation
Bone scintigraphy is a classical imaging modality. However, it continues to be the first choice for surveying the entire body at once, and it can indicate the need for additional imaging when bone metastasis is suspected. 4 As the nature of bone metastasis is osteoblastic in patients with prostate cancer, bone scintigraphy can visualize abnormalities as hot spots or localized accumulation. Although hot spots are also common in non-metastatic conditions, such as trauma, degenerative bone changes and infections, it still has convenient characteristics for screening when indications are selected and interpretation is appropriate. However, therapeutic effects might not be easily determined by visual assessment of the number and size of hot spots. The criteria of the Prostate Cancer Clinical Trials Working Group 2 include counting the number of bone metastases and recognizing that two or more metastatic lesions compared with a previous imaging assessment are signs of exacerbation. 5 EOD analysis classifies <6, 6-20, and >20 hot spots as grades 1, 2 and 3, respectively, and involvement of >75% of the ribs, vertebrae and pelvic bones (super scan) as grade 4.
6-8 However, counting hot spots could still be subjective, and thus a more objective quantitative methodology has been sought from the viewpoint of clinical and investigative purposes.
History of BSI
Investigators at Memorial Sloan-Kettering Cancer Center (New York, NY, USA) developed the BSI during 1977 as a promising means of measuring bone metastasis. 2 The initial method was semiautomatic, but the manual steps were laborious and the metric was not widely applied. A Swedish group then developed a method based on an ANN to completely automate the analysis of whole-body bone scans. The ANN is an artificial intelligence that is trained using examples derived from large databases, 9 and it was initially used as a tool to support clinical decisions due to having acceptable and reproducible diagnostic accuracy. 10 The tool was further developed to calculate BSI. The steps for the automated computer analysis somewhat follow the actual diagnostic steps that are taken by humans, namely the detection, characterization and judgment of severity of abnormalities. The software is now available as EXINI bone (EXINI Diagnostics, Lund, Sweden).
The BSI was also introduced to Japan as BONENAVI software (FUJIFILM RI Pharma, Tokyo, Japan).
11 After a database project using Japanese patients with prostate, breast and other types of cancer, its diagnostic ability was enhanced and adjusted to the Japanese practice of bone scintigraphy. 12 In addition to diagnostic measurements of the total amount of bone metastases, the BSI is also useful for prognostic purposes. For example, risk for survival among patients with prostate cancer classified as BSI <1.4%, 1.4-5.1% and >5.1% could be clearly stratified. 13 Thus, the prognostic value of the BSI is promising, and it is being applied more frequently.
BSI based on ANN: Steps for calculating BSI
The BSI is automatically processed in seven steps as follows (Fig. 1) . 10 1. Segmentation of whole-body image: A whole-body bone template consisting of 12 regions including the skull, ribs, vertebra, pelvis and extremities is constructed based on the average bone architecture for each sex determined from standard scintigrams.
2. Detection of hot spots: Potentially abnormal regions are identified based on a specific algorithm for detecting hot spots that incorporates the count threshold as well as surrounding structures and physiological distribution.
3. Standardization: Normal bone counts are standardized so that bone images with different timing are shown in the same count density format. As technologists can easily adjust the range of displayed counts, this normalization step is convenient for comparing serial data in the same patient.
4. Hot-spot quantitation: Hot spots are quantified in all possible abnormal regions and segments.
5. Hot-spot classification: Features of hot spots, such as size, shape, intensity and distribution, are determined, and ANN analysis classifies all hot areas into high (≥0.5) and low (<0.5) probabilities of metastasis. These areas are visualized as red and blue areas, respectively, on whole-body images.
Calculation of BSI:
The fraction of the skeleton of each abnormal area with a high probability (>0.5) is determined, and then the BSI is calculated as the sum of all such fractions. As the ANN system is trained to identify bone metastasis, BSI is an indicator of the total amount of bones with metastases in the ideal calculation setting. 
BSI and extent of bone metastasis
In principle, the BSI can be automatically calculated without technologist interaction. 14 However, visualized red (high probability) and blue (low probability) regions that are considered inappropriate can be reclassified. Although processing usually works well, urinary contamination, known traumatic regions and apparent misjudgment, for example, can cause regions to become colored. Although the ANN is trained to recognized metastatic patterns, such minor misjudgment is unavoidable. However, even in the face of minor false positive findings, the automated BSI is sufficiently useful and practical for serial follow-up studies during treatment. The present authors believe that to modify all interpretations in a series of studies is impractical, except for apparent artifactual mistakes in judgment. Furthermore, an ANN value with a probability approximately 0.5 could be on either side of the red and blue areas depending on minor changes during treatment, but this is not a misjudgment of metastasis.
One of the key features of the BSI is that the extent of bone metastasis can be objectively grasped on bone scintigrams (Fig. 2) . The BSI is 0% in patients without metastasis, and it increases with the amount of defined metastases. Multiple metastatic hot spots usually correspond to BSI >1%. Multiple hot spots distributed in whole-body images of bones or super scan usually have a BSI of 5% to ≥10%. The understanding of BSI ranges and bone imaging patterns are convenient to standardize the perception of disease severity and therapeutic changes when patients are referred to or from other hospitals. Analytical validation with a revised algorithm showed the linearity of automated BSI with simulated phantom BSI including ranges of BSI >10%.
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BSI for diagnosis and treatment
The BSI can evaluate therapeutic courses including hormonal therapy and chemotherapy, and could thus serve as a biomarker of bone metastasis instead of various chemical markers of bone and tumor markers. The BSI closely correlates with the bone metabolic markers, pyridinoline crosslinked carboxy-terminal telopeptide of type I collagen, bone alkaline phosphatase and tartrate-resistant acid phosphatase5b, and the correlation is closest with log (bone alkaline phosphatase). 16 In contrast, the correlation with PSA is only fair. The EOD can be graded based on the number of hot spots as described above. However, the BSI can be more effective than such crude visual grading, and reflect changes in therapeutic responses more appropriately than visual interpretation. Figure 3 shows a patient with prostate cancer. Anti-androgen therapy including bicalutamide significantly decreased bone metastasis while PSA values increased during the first year. Therapy with radium-223 (Xofigo; Bayer Yakuhin, Tokyo, Japan) significantly decreased the BSI during the second year, showing that the treatment of bone metastasis was effective.
BSI for prognosis
A promising application of BSI is prognostic evaluation. A study of patients with CRPC found that a doubled BSI results in a 1.9-fold increase in the risk of death. 17 Bivariate analysis showed that a change in BSI adjusted for PSA is prognostic at 3 and 6 months of treatment, whereas PSA is not prognostic if adjusted for BSI. The overall survival is similarly longer for patients with CRPC and a reduced automatic BSI than for other patients. 18 Whereas the Gleason score and BSI are associated with the survival of patients with high-risk prostate cancer undergoing primary hormonal therapy, clinical stage and PSA are not prognostic. 19 These findings showed that the BSI might play roles in predicting outcomes and selecting appropriate treatment strategies.
Perspectives in Japan
The diagnostic accuracy of BONENAVI software was investigated on its introduction in Japan, and initial training proceeded using a single-center database. 20 A Japanese bone atlas that fit the population was also added. 21 To further enhance its diagnostic ability, the ANN system was re-trained in a multicenter database project using a new set of 1532 patients. 12 The training databases included 451 and 624 patients with prostate and breast cancer, respectively. The diagnostic accuracy of the re-trained ANN system was significantly better in the validation group (n = 503), compared with the training data in Sweden and the initial training data in Japan. The area under the receiver operating characteristic curve was 0.96 (sensitivity 94%, specificity 88%) for prostate cancer, and 0.92 for breast cancer, showing good diagnostic accuracy (Fig. 4) .
Although high diagnostic accuracy is a good basis for the accurate determination of metastatic cancer, a more attractive use of BSI would be for monitoring treatment and prognosis. A Japanese multicenter registry of patients with prostate cancer (PROSTAT-BSI study: Prostate cancer Registry Of STandard hormonal And chemo Therapy using Bone Scan Index) started to evaluate the role of BSI during hormonal treatment and chemotherapy. By the end of 2016, 237 patients were registered from 36 hospitals based on collaborations among Departments of Urology, Radiology and Nuclear Medicine in Japan. The role of BSI in the management of patients with prostate cancer will be analyzed after a followup period of 3 years. A new phase 2 clinical study is under investigation in patients with CRPC (JapicCTI-163448) in Japan to assess the efficacy and safety of TAS-115 (vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor; Taiho Pharmaceutical, Tokyo, Japan). 22 The primary outcome of that study uses BSI calculated with BONE-NAVI software. BSI could be a good surrogate marker for evaluating the effects of potentially useful new drugs for bone metastasis.
Recent literature related to BSI and prognosis in patients with prostate cancer is summarized in Table 1 . Although several threshold values have been used for survival analysis, such as BSI of 1% and 5%, in general, BSI of >1% resulted in progression, shorter overall survival or higher incidence of cancer death. An increase and decrease in BSI during treatment are also related to worsening and improvement in prognosis, respectively.
European and North American perspectives
Investigators in Sweden and at the Memorial Sloan-Kettering Cancer Center have collaborated to qualify BSI as an imaging biomarker. This work has comprised the pre-analytical, analytical and clinical validation of the automated, objective method of calculating BSI.
The effect of variability in image acquisition on the BSI calculation was analyzed during the pre-analytical validation. 30 The results showed that the BSI is dependent on the quality of anterior and posterior images defined as counts, but not on vendor-specific gamma cameras. It is therefore recommended that the scan speed be adjusted to ensure that the total count is ≥1.5 million per image; that is, to adhere to the guidelines of the Society of Nuclear Medicine and Molecular Imaging.
The analytical validation showed that BSI is an accurate, precise and reproducible method for quantitatively assessing tumor burden. 15 The pre-analytical and analytical studies incorporated both simulated bone scans and studies of actual patients. The advantage of the simulated phantom studies is that tumor burden is known and can be predefined.
The third step in the validation process clinically validates BSI as a prognostic imaging biomarker for overall survival, radiographic progression-free survival and symptomatic skeleton-related events. Bone images from a phase 2 clinical trial were analyzed, and the results showed that BSI and changes in BSI during treatment are independently associated with Receiver operating characteristic analyses. Curves were generated from patients with (a) prostate and (b) breast cancer. The artificial neural network of the software was trained using databases in Sweden (EXINI bone; EB), Japan (BONENAVI 1; BN1) and revised in Japan (BN2). The area under the receiver operating characteristic curve (AUC) is equally high in patients with prostate cancer, but improved with BN2 in patients with breast cancer. overall survival in men with metastatic CRPC. 26 Images from a phase 3 trial are currently under evaluation.
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The latest technical development is the introduction of a web-based service for calculating BSI for the North American market that has resulted in a validated imaging biomarker that is now available for clinical applications.
Conclusion
The new imaging biomarker BSI is a quantitative index of the total amount of bone metastasis determined based on the application of a neural network trained using a large number of learning databases. The development of novel drugs and internal radiation therapy for extending a better QOL requires an optimal surrogate marker of bone metastasis. Although the worldwide use of BSI is increasing, appropriate understanding, and the effective use of a computer-assisted diagnostic and management system will be required.
